| Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria (NCT05843851) | Cystinose Stiftung | 2022-03-15 |
| Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function (NCT05001269) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2022-02-22 |
| Phenotyping of Primary Hyperoxaluria (NCT05107830) | University Hospital, Strasbourg, France | 2021-01-22 |
| A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (NCT04152200) | Alnylam Pharmaceuticals | 2020-01-21 |
| Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria (NCT03819647) | Biocodex | 2019-05-21 |
| A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 (NCT03905694) | Alnylam Pharmaceuticals | 2019-04-22 |
| Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia (NCT03391804) | Allena Pharmaceuticals | 2018-07-17 |
| An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1 (NCT03350451) | Alnylam Pharmaceuticals | 2018-04-04 |
| A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria (NCT03116685) | OxThera | 2018-01-09 |
| Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria (NCT03392896) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2017-12-06 |
| Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis (NCT02000219) | OxThera | 2014-05-19 |
| Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria (NCT02012985) | OxThera | 2013-12-01 |
| Primary Hyperoxaluria Mutation Genotyping/Phenotyping (NCT02340689) | Mayo Clinic | 2013-10-01 |
| Health-related Quality of Life in Rare Kidney Stone (NCT02124395) | NYU Langone Health | 2013-08-01 |
| Rare Kidney Stone Consortium Biobank (NCT02026388) | Mayo Clinic | 2013-05-01 |
| Phase 2/3 Oxabact Study (NCT01037231) | OxThera | 2009-12-01 |
| National Registry of Rare Kidney Diseases (NCT06065852) | UK Kidney Association | 2009-11-06 |
| Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients (NCT00638703) | OxThera | 2007-10-01 |
| Primary Hyperoxaluria Mutation Genotyping (NCT00589225) | Mayo Clinic | 2003-12-01 |
| International Registry for Primary Hyperoxaluria (NCT00875823) | Mayo Clinic | 2003-09-01 |
| Rare Kidney Stone Consortium Patient Registry (NCT00588562) | Mayo Clinic | 2003-07-01 |
| Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1 (NCT04125472) | Alnylam Pharmaceuticals | |